CORRESP Filing
Tonix Pharmaceuticals Holding Corp.
Date: Aug. 29, 2025 · CIK: 0001430306 · Accession: 0001999371-25-012337
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-287965
Letter
Tonix Pharmaceuticals Holding Corp.
26 Main Street, Suite 101
Chatham, New Jersey 07928
August 29, 2025
VIA EDGAR
United States Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, D.C. 20549
Re: Tonix Pharmaceuticals Holding Corp.
Registration Statement on Form S-3 (File No. 333-287965)
Filed on June 12, 2025
Ladies and Gentlemen:
In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. hereby requests that the above-referenced Registration Statement (the " Registration Statement ") be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on September 3, 2025, or as soon as practicable thereafter.
Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions.
Very truly yours,
TONIX PHARMACEUTICALS HOLDINGS CORP.
Show Raw Text
CORRESP 1 filename1.htm Tonix Pharmaceuticals Holding Corp. 26 Main Street, Suite 101 Chatham, New Jersey 07928 August 29, 2025 VIA EDGAR United States Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Tonix Pharmaceuticals Holding Corp. Registration Statement on Form S-3 (File No. 333-287965) Filed on June 12, 2025 Ladies and Gentlemen: In accordance with Rule 461 under the Securities Act of 1933, as amended, Tonix Pharmaceuticals Holding Corp. hereby requests that the above-referenced Registration Statement (the " Registration Statement ") be declared effective by the Securities and Exchange Commission at 4:00 p.m., Eastern Time, on September 3, 2025, or as soon as practicable thereafter. Please call Irina Ishak of Lowenstein Sandler LLP at (973) 422-6406 to confirm the effectiveness of the Registration Statement or with any questions. Very truly yours, TONIX PHARMACEUTICALS HOLDINGS CORP. By: /s/ Bradley Saenger Name: Bradley Saenger Title: Chief Financial Officer